Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation.

BACKGROUND

We aimed to evaluate the pharmacokinetic profile of tigecycline in plasma and its penetration to sputum in moderately ill patients with an infectious acute exacerbation of chronic obstructive pulmonary disease (COPD).

METHODS

Eleven patients hospitalized with acute respiratory failure due to an acute COPD exacerbation with clinical evidence of an infectious cause received tigecycline 50 mg twice daily after an initial loading dose of 100 mg. Blood and sputum samples were collected at steady state after dose seven.

RESULTS

In plasma, mean C pl was 975.95 ± 490.36 ng/mL and mean C pl was 214.48 ±140.62 ng/mL. In sputum, mean C was 641.91 ± 253.07 ng/mL and mean C was 308.06 ± 61.7 ng/mL. In plasma, mean AUC was 3765.89 ± 1862.23 ngh/mL, while in sputum mean AUC was 4023.27 ± 793.37 ngh/mL. The mean penetration ratio for the 10/11 patients was 1.65 ± 1.35. The mean Free AUC/MIC ratio for and was 25.10 ± 12.42 and 6.02 ± 2.97, respectively.

CONCLUSIONS

Our findings support the clinical effectiveness of tigecycline against commonly causative bacteria in COPD exacerbations and highlight its sufficient lung penetration in pulmonary infections of moderate severity.